Barclays
KAPA

Barclays’s Kairos Pharma KAPA Stock Holding History

Barclays’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277 Buy
+103
New +$374 ﹤0.01% 5073

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's KAPA Position: Q2 2026 in Review

Barclays opened a new position in Kairos Pharma (KAPA) in Q2 2026: 103 shares worth $277. The stake represents ﹤0.01% of the portfolio and ranks #5073 among its holdings.

14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

  • Barclays held 103 shares of Kairos Pharma worth $277 as of Q2 2026.
  • Kairos Pharma was a new Barclays position in Q2 2026.
  • Kairos Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5073 holding.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.